Pharmaceutical Executive-12-01-2016

Cleveland Clinic looks at the big medical innovations in store for 2017.

In a continent marked by stark differences in governance, growth and market potential, the best bets must be pursued off script.

How a strong corporate board can help ignite success in these regions.

Pharm Exec sits down with veteran journalist Paula Apsell, the driving force behind the long-running PBS science series NOVA. Apsell offers straightforward advice to the biopharma industry: make your business a business of inspiration, where the return is measured in passion-and the sheer, simple pleasure of finding things out.

How a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.

Republican control of Washington promises overhaul of healthcare and medical product regulation.

How the need for biopharma innovation extends to questions around executive compensation.

Despite Big Pharma's success in translating discovery research into products with proven clinical value, the industry continues to struggle in positioning medical research to the public as a distinctive force for good.

That may be one option as the UK agency, like the NIH it supports, looks at how to generate big savings.

In a regional context marked by chronic instability and turmoil in strategic Latin American economies such as Brazil and Venezuela, Mexico has continually strengthened its positioning as a destination of choice for the global pharmaceutical industry.

Click the title above to open the Pharmaceutical Executive December 2016 issue in an interactive PDF format.